Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
LEXXW 
Lexaria Bioscience Corp (LEXXW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/27/2025: LEXXW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -16.23% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 33.79M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.94 | 52 Weeks Range 0.11 - 2.00 | Updated Date 04/17/2025 |
52 Weeks Range 0.11 - 2.00 | Updated Date 04/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1581.04% |
Management Effectiveness
Return on Assets (TTM) -77.6% | Return on Equity (TTM) -145.55% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 16302820 |
Shares Outstanding - | Shares Floating 16302820 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Lexaria Bioscience Corp
Company Overview
History and Background
Lexaria Bioscience Corp. focuses on drug delivery innovation. Founded to improve bioavailability of active pharmaceutical ingredients, particularly using its DehydraTECHu2122 technology, the company has evolved from cannabis applications to broader pharmaceutical uses.
Core Business Areas
- DehydraTECHu2122 Technology: Lexaria's core business revolves around its patented DehydraTECHu2122 drug delivery technology. This technology enhances the way active pharmaceutical ingredients (APIs) enter the bloodstream, potentially increasing efficacy and reducing side effects.
- Pharmaceutical Applications: Focuses on developing and out-licensing DehydraTECHu2122 for various therapeutic areas, including hypertension, diabetes, and neurological disorders. Conducting research and development to demonstrate DehydraTECHu2122 efficacy and safety.
Leadership and Structure
Chris Bunka serves as the CEO. The company has a board of directors providing oversight. The organizational structure includes R&D, business development, and intellectual property management teams.
Top Products and Market Share
Key Offerings
- DehydraTECHu2122: This drug delivery technology is Lexaria's primary offering. It aims to improve the oral bioavailability of various drugs. It does not have direct market share as it is a technology platform licensed to other companies. Competitors include companies that specialize in drug delivery technologies, as well as large pharmaceutical companies with internal drug delivery programs.
Market Dynamics
Industry Overview
The pharmaceutical drug delivery market is large and growing, driven by the need for more effective and patient-friendly drug formulations. Nanotechnology, microencapsulation, and other advanced delivery systems are competing for market share.
Positioning
Lexaria positions itself as an innovator in drug delivery with its DehydraTECHu2122 platform, focusing on out-licensing and partnerships with pharmaceutical companies. Its advantage lies in the potential for improved bioavailability and faster onset of action.
Total Addressable Market (TAM)
The global drug delivery market is projected to reach hundreds of billions of USD. Lexaria's TAM is the portion addressable through improved bioavailability via oral administration and licensing of its technology.
Upturn SWOT Analysis
Strengths
- Patented DehydraTECHu2122 technology
- Potential for improved bioavailability
- Focus on out-licensing model
- Research and Development
- Intellectual Property
Weaknesses
- Reliance on out-licensing success
- Limited financial resources
- Small size and market presence
- Dependence on third-party validation
- Cash Burn
Opportunities
- Partnerships with pharmaceutical companies
- Expansion into new therapeutic areas
- Increasing demand for better drug delivery systems
- Regulatory approvals for DehydraTECHu2122-enhanced drugs
- Further development of intellectual property and technologies
Threats
- Competition from established drug delivery technologies
- Regulatory hurdles
- Failure to secure licensing agreements
- Patent infringement
- Changes in pharmaceutical industry trends
Competitors and Market Share
Key Competitors
Competitive Landscape
The drug delivery market is competitive, with established players having strong resources and existing partnerships. Lexariau2019s advantage lies in the innovative DehydraTECHu2122 platform, but they face the challenge of demonstrating its superiority and securing adoption by large pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been minimal due to the pre-revenue stage of the company, primarily consisting of research and development activities.
Future Projections: Future growth depends on successful out-licensing agreements and regulatory approvals. Analyst projections are dependent on achieving these milestones.
Recent Initiatives: Lexaria has been focused on conducting clinical trials to validate the efficacy of DehydraTECHu2122 and pursuing strategic partnerships. They are focusing on Hypertension research at the moment.
Summary
Lexaria Bioscience Corp. is a speculative stock focused on its DehydraTECHu2122 drug delivery technology. The company's strengths lie in its patented technology and potential for improved drug bioavailability. Challenges include limited resources, reliance on partnerships, and competition from established players. Successful out-licensing is critical for future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Lexaria Bioscience Corp. Investor Relations
- Company Press Releases
- Third-party financial data providers (e.g., SEC Filings)
- Industry News
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on thorough research and consultation with a qualified financial advisor. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lexaria Bioscience Corp
Exchange NASDAQ | Headquaters Kelowna, BC, Canada | ||
IPO Launch date 2021-01-12 | CEO & Director Mr. Richard C. Christopher | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://lexariabioscience.com |
Full time employees 7 | Website https://lexariabioscience.com | ||
Lexaria Bioscience Corp. operates as a biotechnology company. It offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids. Its DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, creams, lotions, and skin patches; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.